Video wird geladen...

Video konnte nicht geladen werden

Zur Startseite

🔴Promising new data: Red light therapy is showing real results in Parkinson's disease clinical trials — gait improves, tremors ease, and new brain imaging suggests it may actually protect dopamine neurons. This isn't fringe science. It's peer-reviewed. Here's what the data shows 🧵👇 #Parkinsons #NeurologyResearch

Neuroscope_mp's profile picture

Harshi Peiris, Ph.D.

11,122 subscribers

35,709 Aufrufe • vor 3 Monaten •via X (Twitter)

LIVE

Anya Rossi• Live Now

Private livecam show

0 Kommentare

Keine Kommentare verfügbar

Kommentare vom Original-Post werden hier angezeigt

Ähnliche Videos

🚨 BREAKING: Most people don't know that certain diseases dramatically raise their risk of developing Parkinson's. This isn't speculation. It's peer-reviewed science involving millions of patients. Some of these conditions are treatable, and treating them may lower your risk. Here's what the research actually says 🧵👇
0:23

🚨 BREAKING: Most people don't know that certain diseases dramatically raise their risk of developing Parkinson's. This isn't speculation. It's peer-reviewed science involving millions of patients. Some of these conditions are treatable, and treating them may lower your risk. Here's what the research actually says 🧵👇

Harshi Peiris, Ph.D.

12,648 Aufrufe • vor 4 Monaten

🚨 BREAKING Scientists may have just cracked the code on Alzheimer's and Parkinson's — WITH ONE PILL. A drug called Buntanetap was just published in a peer-reviewed journal with Phase 3 data. Phase 3 means that we are on the verge of FDA approval. It targets the ROOT CAUSE of both diseases simultaneously. Here's what you need to know 🧵👇 #Alzheimers #Parkinsons
0:20

🚨 BREAKING Scientists may have just cracked the code on Alzheimer's and Parkinson's — WITH ONE PILL. A drug called Buntanetap was just published in a peer-reviewed journal with Phase 3 data. Phase 3 means that we are on the verge of FDA approval. It targets the ROOT CAUSE of both diseases simultaneously. Here's what you need to know 🧵👇 #Alzheimers #Parkinsons

Harshi Peiris, Ph.D.

503,910 Aufrufe • vor 3 Monaten

Check out the unusual gait pattern worsened by levodopa in this case of a PARKIN gene related Parkinson's. This is why we call it Parkinson's diseases plural as there are so many different manifestations, with or without known gene mutations. Nice case by Mehta and colleagues in Movement Disorders Clinical Practice. Key Points: - 26 year old Parkin gene-related early-onset Parkinson's. - Paradoxical response to levodopa, dopamine worsened dystonia. - Amantadine seemed to help. - Complaint was tightness of lower limbs when walking. - Had heterozygous PRKN mutations, w/ a 'missense pathogenic mutation in exon 7 (c.850G > C (p. Gly284Arg) and a deletion mutation in exon 3 (241 bp),' - 'Forward walking was characterized by bilateral hip flexion and abduction, flexed knees, ankle inversion and plantar flexion rebound during the stance phase on the left foot and reduced arm swing bilaterally.' My take: Some of these PARKIN and genetic PD cases may respond to anticholinergics or dopamine agonists, however in this case this was not helpful. The improvement w/ amantadine was humbling and unexpected. The authors suggest to us to try amantadine, if dopamine is worsening dystonia or gait in the setting of PARKIN. 'Parkinsons diseases, every day we learn something new.' A close look at the video suggests the amantadine helped however did not resolve the challenge. DBS may be a reasonable next step to consider. #Parkinsons
1:41

Check out the unusual gait pattern worsened by levodopa in this case of a PARKIN gene related Parkinson's. This is why we call it Parkinson's diseases plural as there are so many different manifestations, with or without known gene mutations. Nice case by Mehta and colleagues in Movement Disorders Clinical Practice. Key Points: - 26 year old Parkin gene-related early-onset Parkinson's. - Paradoxical response to levodopa, dopamine worsened dystonia. - Amantadine seemed to help. - Complaint was tightness of lower limbs when walking. - Had heterozygous PRKN mutations, w/ a 'missense pathogenic mutation in exon 7 (c.850G > C (p. Gly284Arg) and a deletion mutation in exon 3 (241 bp),' - 'Forward walking was characterized by bilateral hip flexion and abduction, flexed knees, ankle inversion and plantar flexion rebound during the stance phase on the left foot and reduced arm swing bilaterally.' My take: Some of these PARKIN and genetic PD cases may respond to anticholinergics or dopamine agonists, however in this case this was not helpful. The improvement w/ amantadine was humbling and unexpected. The authors suggest to us to try amantadine, if dopamine is worsening dystonia or gait in the setting of PARKIN. 'Parkinsons diseases, every day we learn something new.' A close look at the video suggests the amantadine helped however did not resolve the challenge. DBS may be a reasonable next step to consider. #Parkinsons

Michael Okun

16,865 Aufrufe • vor 2 Jahren

What if your personal data became an asset you actually owned? In this May 2026 AMA, Matrix AI Network explores one of the most important questions facing AI, Web3, and the future digital economy: Who owns the data that powers artificial intelligence? As AI models continue to improve, the next major bottleneck is no longer computing power—it is access to high-quality, verified human data. The discussion covers how personal biodata can become a valuable digital asset, how data quality is measured, and why future AI companies may depend directly on users as data providers. Topics include: ✅ Biodata as a new asset class ✅ AI-grade data quality scoring ✅ Wearable devices for raw data ✅ Data ownership and monetization models ✅ Preventing fake data and device spoofing ✅ Real-world applications in healthcare, sports science and mental wellness ✅ Hypnus and the future biodata ecosystem ✅ Project direction The future may not belong to companies that own data. It belongs to the people who create it. Watch now 👇 #AI #Web3 #DataOwnership
29:51

What if your personal data became an asset you actually owned? In this May 2026 AMA, Matrix AI Network explores one of the most important questions facing AI, Web3, and the future digital economy: Who owns the data that powers artificial intelligence? As AI models continue to improve, the next major bottleneck is no longer computing power—it is access to high-quality, verified human data. The discussion covers how personal biodata can become a valuable digital asset, how data quality is measured, and why future AI companies may depend directly on users as data providers. Topics include: ✅ Biodata as a new asset class ✅ AI-grade data quality scoring ✅ Wearable devices for raw data ✅ Data ownership and monetization models ✅ Preventing fake data and device spoofing ✅ Real-world applications in healthcare, sports science and mental wellness ✅ Hypnus and the future biodata ecosystem ✅ Project direction The future may not belong to companies that own data. It belongs to the people who create it. Watch now 👇 #AI #Web3 #DataOwnership

Matrix AI Network

61,436 Aufrufe • vor 3 Monaten

📹 Discover the latest clinical practice changing insights from the ENETS 2026 conference in Krakow, Poland. Prof. Louis de Mestier, Prof. Timon Vandamme, and Dr Alice Durand share insights into new data on PRRT in treatment sequencing and re-challenge in NETs, obrixtamig as 1st line therapy in advanced NEC, and the role of surgery in stage 1–3 disease. In addition, they discuss interesting combination treatment. How will new data impact clinical practice? Watch to find out. This educational programme is supported by an Independent Educational Grant from Ipsen. The content published on this website is under the responsibility of its authors. Some scientific data published on this website may not have been validated by the relevant Marketing Authorisation Committees and should not be put into practice. It should be read and understood with the utmost discernment and is provided for the purpose of disseminating information on the current state of research to the international scientific community.
5:56

📹 Discover the latest clinical practice changing insights from the ENETS 2026 conference in Krakow, Poland. Prof. Louis de Mestier, Prof. Timon Vandamme, and Dr Alice Durand share insights into new data on PRRT in treatment sequencing and re-challenge in NETs, obrixtamig as 1st line therapy in advanced NEC, and the role of surgery in stage 1–3 disease. In addition, they discuss interesting combination treatment. How will new data impact clinical practice? Watch to find out. This educational programme is supported by an Independent Educational Grant from Ipsen. The content published on this website is under the responsibility of its authors. Some scientific data published on this website may not have been validated by the relevant Marketing Authorisation Committees and should not be put into practice. It should be read and understood with the utmost discernment and is provided for the purpose of disseminating information on the current state of research to the international scientific community.

NET CONNECT powered by COR2ED

1,109,836 Aufrufe • vor 5 Monaten

Dr. Patrick Soon-Shiong dropped a cancer paradigm shift that could change everything: “Cancer isn’t the disease — it’s the symptom. The real disease is the collapse of your immune system.” Instead of destroying the body with aggressive treatments, he says we should focus on rebuilding and supporting the immune system so it can actually fight back. No single magic bullet, but the science is finally moving fast — and he’s calling for more clinical trials to turn this new understanding into real results. This one idea flips the entire approach to cancer treatment on its head. What do you think — could shifting from attacking cancer to strengthening the immune system be the breakthrough we’ve been waiting for, or is it still too early to tell?
0:40

Dr. Patrick Soon-Shiong dropped a cancer paradigm shift that could change everything: “Cancer isn’t the disease — it’s the symptom. The real disease is the collapse of your immune system.” Instead of destroying the body with aggressive treatments, he says we should focus on rebuilding and supporting the immune system so it can actually fight back. No single magic bullet, but the science is finally moving fast — and he’s calling for more clinical trials to turn this new understanding into real results. This one idea flips the entire approach to cancer treatment on its head. What do you think — could shifting from attacking cancer to strengthening the immune system be the breakthrough we’ve been waiting for, or is it still too early to tell?

Camus

35,900 Aufrufe • vor 5 Monaten

Can you pick out who has Parkinson's disease from the video using the 'whistle-smile' reflex? Maybe? Frederic Hanes described this sign in 1943. Giulia Paparella and colleagues revisit the observation in a trial of 34 Parkinson's folks versus 34 healthy controls in Movement Disorders Clinical Practice. Key Points: - When healthy individuals are prompted to whistle during a medical examination, 'they typically comply and subsequently smile.' - In Parkinson's 'they execute the whistle but often fail to produce an immediate smile.' - In their study they showed a sensitivity of 76% and a specificity of 65% for the sign. My take: It is hard to believe that there are only two papers on this sign published since 1943. Behavioral neurologists have long been fascinated by spontaneous smiling versus posed and elicited smiling in Parkinson's disease. Though the sensitivity and specificity are too low to become a biomarker, this is a sign neurologists can keep in their pockets for teaching. Researchers may also consider studying this phenomenon with functional imaging as the limbic-motor newtowrk is fascinating and we have also observed DBS induced smiling. The brain is a fascinating supercomputer and frankly, we do not know what we do not know. Ecce signum – behold the sign of the smile in Parkinson's. #Parkinsons Smiles induced by DBS: Spontaneous and posed smiles in Parkinson: Motor cortex and facial smiling in primates by Morecraft: #Parkinsons #smilefest2024 #smile
0:25

Can you pick out who has Parkinson's disease from the video using the 'whistle-smile' reflex? Maybe? Frederic Hanes described this sign in 1943. Giulia Paparella and colleagues revisit the observation in a trial of 34 Parkinson's folks versus 34 healthy controls in Movement Disorders Clinical Practice. Key Points: - When healthy individuals are prompted to whistle during a medical examination, 'they typically comply and subsequently smile.' - In Parkinson's 'they execute the whistle but often fail to produce an immediate smile.' - In their study they showed a sensitivity of 76% and a specificity of 65% for the sign. My take: It is hard to believe that there are only two papers on this sign published since 1943. Behavioral neurologists have long been fascinated by spontaneous smiling versus posed and elicited smiling in Parkinson's disease. Though the sensitivity and specificity are too low to become a biomarker, this is a sign neurologists can keep in their pockets for teaching. Researchers may also consider studying this phenomenon with functional imaging as the limbic-motor newtowrk is fascinating and we have also observed DBS induced smiling. The brain is a fascinating supercomputer and frankly, we do not know what we do not know. Ecce signum – behold the sign of the smile in Parkinson's. #Parkinsons Smiles induced by DBS: Spontaneous and posed smiles in Parkinson: Motor cortex and facial smiling in primates by Morecraft: #Parkinsons #smilefest2024 #smile

Michael Okun

12,724 Aufrufe • vor 2 Jahren

10 Shocking Stories the Media Buried This Week #10 - FDA approves clinical trials for new “pandemic” vaccine. - The trials are funded by BARDA (so your tax dollars) - The words “pandemic vaccine” are in the study's title (weird) - It's for bird flu - The most chilling thing is the “vaccine” uses lipid nanoparticles and self-amplifying RNA technology. Self-amplifying RNA (saRNA) technology allows the RNA to essentially “photocopy” itself inside the body without an off switch. Dr. Jessica Rose (Jessica Rose 🤙) describes the new vaccine candidate as “gain-of-function” inside the human body. She writes, “Based on evidences collected over the past four years from peer-reviewed literature and FOIA requested data, it is more likely than not that this is the priming of/grooming of the public for the next ‘planned pandemic.’ I mean, it’s in the clinical trial name.” Dr. Jessica Rose joins the show to elaborate on her concerns. This conversation is a jaw-dropper. (See 9 More Revealing Stories Below)
27:37

10 Shocking Stories the Media Buried This Week #10 - FDA approves clinical trials for new “pandemic” vaccine. - The trials are funded by BARDA (so your tax dollars) - The words “pandemic vaccine” are in the study's title (weird) - It's for bird flu - The most chilling thing is the “vaccine” uses lipid nanoparticles and self-amplifying RNA technology. Self-amplifying RNA (saRNA) technology allows the RNA to essentially “photocopy” itself inside the body without an off switch. Dr. Jessica Rose (Jessica Rose 🤙) describes the new vaccine candidate as “gain-of-function” inside the human body. She writes, “Based on evidences collected over the past four years from peer-reviewed literature and FOIA requested data, it is more likely than not that this is the priming of/grooming of the public for the next ‘planned pandemic.’ I mean, it’s in the clinical trial name.” Dr. Jessica Rose joins the show to elaborate on her concerns. This conversation is a jaw-dropper. (See 9 More Revealing Stories Below)

The Vigilant Fox 🦊

1,844,119 Aufrufe • vor 1 Jahr

Dr. Ruxandra Teslo argues America's biotech problem isn't the science, it's how slowly we learn from humans: "This is going to be more and more of a bottleneck as science advances especially in oncology. It's not just that we don't have enough clinical trials and they are expensive. This has become worse and worse throughout the years." "The article is particularly focused on these phase one clinical trials. These are the trials where you first take a new drug into humans for the first time. The reason we're focusing on those, they are some of the most important trials because that's where you can actually start to learn and do iterative loops of learning in humans." "What you learn from that goes back into the science and you can engineer something better. We can see from China, they're very very good doing their phase one trials fast, that is very much responsible for propelling them ahead, almost ahead of the US in just a decade, despite the fact that their science is not as good." "We have a very good model for how to do them faster and better, which is Australia." Ruxandra Teslo 🧬 Adam Kroetsch IFP
2:32

Dr. Ruxandra Teslo argues America's biotech problem isn't the science, it's how slowly we learn from humans: "This is going to be more and more of a bottleneck as science advances especially in oncology. It's not just that we don't have enough clinical trials and they are expensive. This has become worse and worse throughout the years." "The article is particularly focused on these phase one clinical trials. These are the trials where you first take a new drug into humans for the first time. The reason we're focusing on those, they are some of the most important trials because that's where you can actually start to learn and do iterative loops of learning in humans." "What you learn from that goes back into the science and you can engineer something better. We can see from China, they're very very good doing their phase one trials fast, that is very much responsible for propelling them ahead, almost ahead of the US in just a decade, despite the fact that their science is not as good." "We have a very good model for how to do them faster and better, which is Australia." Ruxandra Teslo 🧬 Adam Kroetsch IFP

MTS

16,475 Aufrufe • vor 20 Tagen

Your agents can't keep up with real-time data. Especially when it's scattered across dozens of sources. Most teams waste weeks building custom connectors for every database, API, and data warehouse. Then they build ETL pipelines to sync everything. By the time your agent retrieves the data, it's already outdated. Picture this: Your Postgres database updated 5 minutes ago. Your MongoDB collection changed 2 minutes ago. Your agent is still pulling from yesterday's snapshot. This is why most production RAG systems fail. There's a better approach: MindsDB is an open-source AI platform with a federated data engine that lets you query multiple data sources in real-time using SQL - without moving any data. Here's what makes it different: ↳ Your data stays in place. No ETL pipelines or data duplication ↳ Query Postgres, MongoDB, REST APIs, and more using consistent SQL ↳ JOIN across different sources in real-time with a unified interface ↳ Works with both structured and un-structured data And here's the best part: You don't even need to write SQL. Just describe what you want in plain English, and MindsDB converts it to SQL automatically. The system does all the heavy lifting. The breakthrough for AI agents is simple: When data updates at the source, your agent gets fresh results immediately. No sync delays. No stale embeddings. No custom code for each integration. You can literally write a SQL query that joins a Postgres table with a MongoDB collection and gets live results. This is what production AI applications need but rarely get. In this video, I give you a complete walkthrough of what we just discussed and how to actually do it. Make sure you watch this till the end. I've shared the link to MindsDB's GitHub repo in the next tweet!
9:28

Your agents can't keep up with real-time data. Especially when it's scattered across dozens of sources. Most teams waste weeks building custom connectors for every database, API, and data warehouse. Then they build ETL pipelines to sync everything. By the time your agent retrieves the data, it's already outdated. Picture this: Your Postgres database updated 5 minutes ago. Your MongoDB collection changed 2 minutes ago. Your agent is still pulling from yesterday's snapshot. This is why most production RAG systems fail. There's a better approach: MindsDB is an open-source AI platform with a federated data engine that lets you query multiple data sources in real-time using SQL - without moving any data. Here's what makes it different: ↳ Your data stays in place. No ETL pipelines or data duplication ↳ Query Postgres, MongoDB, REST APIs, and more using consistent SQL ↳ JOIN across different sources in real-time with a unified interface ↳ Works with both structured and un-structured data And here's the best part: You don't even need to write SQL. Just describe what you want in plain English, and MindsDB converts it to SQL automatically. The system does all the heavy lifting. The breakthrough for AI agents is simple: When data updates at the source, your agent gets fresh results immediately. No sync delays. No stale embeddings. No custom code for each integration. You can literally write a SQL query that joins a Postgres table with a MongoDB collection and gets live results. This is what production AI applications need but rarely get. In this video, I give you a complete walkthrough of what we just discussed and how to actually do it. Make sure you watch this till the end. I've shared the link to MindsDB's GitHub repo in the next tweet!

Akshay 🚀

65,672 Aufrufe • vor 10 Monaten

This is IMPORTANT news for parents. A new study is out on January 23rd, 2025, it's peer-reviewed, meaning it's been checked and double-checked by experts. It shows a clear link between vaccines and autism. This isn't just about autism; we're talking about a range of neurodevelopmental disorders. The more vaccines a child gets, the higher the risk. There's even a graph showing this dose-response relationship, where autism rates climb with each vaccine. And for preterm babies? They're at an even higher risk for these issues when vaccinated compared to those who aren't. Now, I know some say autism is just genetic, but this study adds a new layer to the debate. Check out the graphs if you want the hard data. U.S. Senator Bill Cassidy, M.D. Robert F. Kennedy Jr
1:40

This is IMPORTANT news for parents. A new study is out on January 23rd, 2025, it's peer-reviewed, meaning it's been checked and double-checked by experts. It shows a clear link between vaccines and autism. This isn't just about autism; we're talking about a range of neurodevelopmental disorders. The more vaccines a child gets, the higher the risk. There's even a graph showing this dose-response relationship, where autism rates climb with each vaccine. And for preterm babies? They're at an even higher risk for these issues when vaccinated compared to those who aren't. Now, I know some say autism is just genetic, but this study adds a new layer to the debate. Check out the graphs if you want the hard data. U.S. Senator Bill Cassidy, M.D. Robert F. Kennedy Jr

ꪻꫝể ꪻꫝể

65,708 Aufrufe • vor 1 Jahr

“It was like I’d gotten my mind back.” “This lovely calm kind of came into me and it sort of stayed.” These are real quotes from participants in Iain Campbell, Ph.D.'s newly published study in BJPsych Open looking at ketogenic therapy for bipolar disorder that just dropped today! 📃 Read it here: This new study is one of the first to use advanced brain imaging to evaluate the impact ketosis has on bipolar disorder. Combined with blood biomarker data, this study demonstrated that ketosis can lead to favorable brain and metabolite changes which translated to impressive quality of life improvements in the study participants. The participant stories in this video and in the study as a whole are moving and reinforce the urgent need to fight for new treatments for each individual living with bipolar disorder. This new study contributes to the growing body of research supporting the use of ketogenic therapy as a #newbipolartreatment.
2:20

“It was like I’d gotten my mind back.” “This lovely calm kind of came into me and it sort of stayed.” These are real quotes from participants in Iain Campbell, Ph.D.'s newly published study in BJPsych Open looking at ketogenic therapy for bipolar disorder that just dropped today! 📃 Read it here: This new study is one of the first to use advanced brain imaging to evaluate the impact ketosis has on bipolar disorder. Combined with blood biomarker data, this study demonstrated that ketosis can lead to favorable brain and metabolite changes which translated to impressive quality of life improvements in the study participants. The participant stories in this video and in the study as a whole are moving and reinforce the urgent need to fight for new treatments for each individual living with bipolar disorder. This new study contributes to the growing body of research supporting the use of ketogenic therapy as a #newbipolartreatment.

Metabolic Mind

21,804 Aufrufe • vor 1 Jahr

New longevity therapy started: cerebrolysin What is cerebrolysin Cerebrolysin is a mixture of peptides to enhance cognitive function. It fosters neuronal growth and repair which may improve memory. To date, cerebrolysin has been used to treat brain fog, brain injury, and slow down the process of dementia. Because a prior measurement indicated that I have swelling in my brain from my internal jugular vein stenosis (IJVS), we are examining the effectiveness of cerebrolysin in mitigating inflammation as well as any cognitive improvements. Baseline measurements After seeing my brain swelling via MRI from IJVS, we chose to proceed with cerebrolysin. We will be measuring the efficacy by monitoring brain MRI markers, sleeping HRV (3 month average at least, measured using WHOOP) and cognitive testing. Strength of evidence We find that the data on cerebrolysin in human clinical trials is promising. Most trials examine the effects of cerebrolysin on neurodegenerative diseases and the outcomes show consistent benefits in cognition and global clinical function. There is a considerable amount of research suggesting that cerebrolysin can be beneficial in treating neurodegenerative diseases, stroke, and brain injuries. We cannot recommend that anyone else participates until more extensive clinical trials have been performed. Protocol Ten, 5 mL intramuscular injections over 20 days. Cost: $160 What we expect to happen We will be investigating several brain biomarkers to document the effects of cerebrolysin. To measure the effects, we will specifically look at neurotrophic factors and markers of neural damage. MRI can be implemented to measure brain markers.
0:59

New longevity therapy started: cerebrolysin What is cerebrolysin Cerebrolysin is a mixture of peptides to enhance cognitive function. It fosters neuronal growth and repair which may improve memory. To date, cerebrolysin has been used to treat brain fog, brain injury, and slow down the process of dementia. Because a prior measurement indicated that I have swelling in my brain from my internal jugular vein stenosis (IJVS), we are examining the effectiveness of cerebrolysin in mitigating inflammation as well as any cognitive improvements. Baseline measurements After seeing my brain swelling via MRI from IJVS, we chose to proceed with cerebrolysin. We will be measuring the efficacy by monitoring brain MRI markers, sleeping HRV (3 month average at least, measured using WHOOP) and cognitive testing. Strength of evidence We find that the data on cerebrolysin in human clinical trials is promising. Most trials examine the effects of cerebrolysin on neurodegenerative diseases and the outcomes show consistent benefits in cognition and global clinical function. There is a considerable amount of research suggesting that cerebrolysin can be beneficial in treating neurodegenerative diseases, stroke, and brain injuries. We cannot recommend that anyone else participates until more extensive clinical trials have been performed. Protocol Ten, 5 mL intramuscular injections over 20 days. Cost: $160 What we expect to happen We will be investigating several brain biomarkers to document the effects of cerebrolysin. To measure the effects, we will specifically look at neurotrophic factors and markers of neural damage. MRI can be implemented to measure brain markers.

Bryan Johnson

1,072,091 Aufrufe • vor 2 Jahren

🚨 IVERMECTIN AND CANCER: WHAT THE RESEARCH ACTUALLY SHOWS A researcher recently shared what they found after looking into Ivermectin and cancer. They discovered over 300 peer-reviewed papers on PubMed examining Ivermectin in cancer. While most of this research is preclinical (cell lines, mice, and rats), the body of work is extensive and covers many different mechanisms. Key points from the research include: ✅ Ivermectin appears to target cancer stem cells, which standard chemotherapy often does not effectively kill. ✅ It can help reverse multi-drug resistance in cancer cells and may sensitise them to chemotherapy. ✅ It acts as a radio sensitizer, potentially making cancer cells more responsive to radiation. ✅ It can inhibit angiogenesis, limiting the tumor’s ability to form new blood vessels. ✅ It may inhibit enzymes involved in cancer cell detachment and spread, reducing the potential for metastasis. The researcher noted that Ivermectin is an off-patent, low-cost drug. Because of this, there has been little financial incentive to fund large-scale human trials in oncology, which is why most of the data remains preclinical.
5:23

🚨 IVERMECTIN AND CANCER: WHAT THE RESEARCH ACTUALLY SHOWS A researcher recently shared what they found after looking into Ivermectin and cancer. They discovered over 300 peer-reviewed papers on PubMed examining Ivermectin in cancer. While most of this research is preclinical (cell lines, mice, and rats), the body of work is extensive and covers many different mechanisms. Key points from the research include: ✅ Ivermectin appears to target cancer stem cells, which standard chemotherapy often does not effectively kill. ✅ It can help reverse multi-drug resistance in cancer cells and may sensitise them to chemotherapy. ✅ It acts as a radio sensitizer, potentially making cancer cells more responsive to radiation. ✅ It can inhibit angiogenesis, limiting the tumor’s ability to form new blood vessels. ✅ It may inhibit enzymes involved in cancer cell detachment and spread, reducing the potential for metastasis. The researcher noted that Ivermectin is an off-patent, low-cost drug. Because of this, there has been little financial incentive to fund large-scale human trials in oncology, which is why most of the data remains preclinical.

Joe Tippens

20,524 Aufrufe • vor 2 Monaten

FDA Commissioner Dr. Marty Makary revealed a major shift at the agency that’s still making waves: “I personally meet one-on-one with reviewers and ask: ‘Are you seeing anything that gives you chills up your spine because it could be such a game-changer?’” He described the FDA’s new proactive approach: - No more passive waiting for applications. - When early data looks “too good to be true,” they call companies directly: “Forget the paperwork — send more data now.” - Fast-track vouchers for decisions in weeks instead of years. - Recent example: gene therapy restored normal hearing in 3 of 12 deaf children (improved in 7) with perfect safety — FDA contacted the company days after NEJM publication. Makary emphasized the FDA is aggressively tracking promising treatments for blindness, deafness, pediatric/rare diseases, cancers — and a “potentially promising” therapy for type 1 diabetes that has reviewers excited. This is the FDA acting like it’s on the front lines of curing disease, not just regulating it. Months later — are you hopeful this new mindset finally delivers real cures, or waiting to see hard results?
2:31

FDA Commissioner Dr. Marty Makary revealed a major shift at the agency that’s still making waves: “I personally meet one-on-one with reviewers and ask: ‘Are you seeing anything that gives you chills up your spine because it could be such a game-changer?’” He described the FDA’s new proactive approach: - No more passive waiting for applications. - When early data looks “too good to be true,” they call companies directly: “Forget the paperwork — send more data now.” - Fast-track vouchers for decisions in weeks instead of years. - Recent example: gene therapy restored normal hearing in 3 of 12 deaf children (improved in 7) with perfect safety — FDA contacted the company days after NEJM publication. Makary emphasized the FDA is aggressively tracking promising treatments for blindness, deafness, pediatric/rare diseases, cancers — and a “potentially promising” therapy for type 1 diabetes that has reviewers excited. This is the FDA acting like it’s on the front lines of curing disease, not just regulating it. Months later — are you hopeful this new mindset finally delivers real cures, or waiting to see hard results?

Camus

118,516 Aufrufe • vor 6 Monaten

Joe Rogan shocks sunlight expert Rowan Jacobsen after revealing red light therapy completely reversed his vision loss: ROGAN: “Red light therapy took away all the problems I was having with my eyesight. They say to wear goggles, but I just keep my eyes open.” JACOBSEN: “Wow. Light medicine is going to be extremely important in the next 10-20 years.” ROGAN: “Gary Brecka explained red light therapy to me, so I bought one of these expensive full body red light beds.” JACOBSEN: “And that actually improved your vision?” ROGAN: “It didn’t just stop the degeneration, but it actually reversed it. I used to need 3X reading glasses just to read my phone. Within about a month, my vision started improving. Two years later, I don’t need reading glasses at all.” JACOBSEN: “There’s real research showing red light improves mitochondrial function. The eyes use more energy than almost any other cells in the human body.” ROGAN: “Why are dermatologists ignoring evidence that different forms of light can heal the human body?” JACOBSEN: “They’ve really only avoided me. I don’t think they’re ready for this type of research.” ROGAN: “There’s already a tremendous amount of data. I don’t understand how someone can call themselves an expert on skin and ignore light therapy.” JACOBSEN: “They 100% should be experts on all this.” ROGAN: “There’s not a lot of scientists so they need to start doing their job. We can’t just rely on old data. They’re doing the whole field a disservice.”
6:28

Joe Rogan shocks sunlight expert Rowan Jacobsen after revealing red light therapy completely reversed his vision loss: ROGAN: “Red light therapy took away all the problems I was having with my eyesight. They say to wear goggles, but I just keep my eyes open.” JACOBSEN: “Wow. Light medicine is going to be extremely important in the next 10-20 years.” ROGAN: “Gary Brecka explained red light therapy to me, so I bought one of these expensive full body red light beds.” JACOBSEN: “And that actually improved your vision?” ROGAN: “It didn’t just stop the degeneration, but it actually reversed it. I used to need 3X reading glasses just to read my phone. Within about a month, my vision started improving. Two years later, I don’t need reading glasses at all.” JACOBSEN: “There’s real research showing red light improves mitochondrial function. The eyes use more energy than almost any other cells in the human body.” ROGAN: “Why are dermatologists ignoring evidence that different forms of light can heal the human body?” JACOBSEN: “They’ve really only avoided me. I don’t think they’re ready for this type of research.” ROGAN: “There’s already a tremendous amount of data. I don’t understand how someone can call themselves an expert on skin and ignore light therapy.” JACOBSEN: “They 100% should be experts on all this.” ROGAN: “There’s not a lot of scientists so they need to start doing their job. We can’t just rely on old data. They’re doing the whole field a disservice.”

Fan Commentary: Joe Rogan Recaps

285,914 Aufrufe • vor 3 Monaten

🥼DOCTORS DISCRIMINATING AGAINST UNVACCINATED PATIENTS: Practices refusing care, kicking families out, or denying treatment unless parents comply with the full vaccine schedule. This isn't rare; it's happening across the country, leaving parents scrambling for options. In this clip, we confront the real barrier: How do we change doctors' minds and get them to at least LOOK at the evidence showing potential harm? The key? Robust, unbiased research comparing vaccinated vs. unvaccinated kids. The Henry Ford study (featured in "An Inconvenient Study") showed concerning differences, but it was never properly published. We need dozens more like it: peer-reviewed, replicated at places like Harvard, Kaiser, Denmark, and beyond. Dr. Warsh: "If we did 50 studies... everybody's tune would change." Even critics couldn't dismiss solid data showing trends in chronic conditions. It's about true informed consent. If studies showed that vaccinated kids were healthier, that would be great data. (It hasn't ever happened, but it would be great data!) Parents MUST know the true risks as we pile on more shots. Assuming "more is always better" without evidence is reckless. Watch and see why transparency in research is the path to ending this discrimination and restoring trust 👇
2:04

🥼DOCTORS DISCRIMINATING AGAINST UNVACCINATED PATIENTS: Practices refusing care, kicking families out, or denying treatment unless parents comply with the full vaccine schedule. This isn't rare; it's happening across the country, leaving parents scrambling for options. In this clip, we confront the real barrier: How do we change doctors' minds and get them to at least LOOK at the evidence showing potential harm? The key? Robust, unbiased research comparing vaccinated vs. unvaccinated kids. The Henry Ford study (featured in "An Inconvenient Study") showed concerning differences, but it was never properly published. We need dozens more like it: peer-reviewed, replicated at places like Harvard, Kaiser, Denmark, and beyond. Dr. Warsh: "If we did 50 studies... everybody's tune would change." Even critics couldn't dismiss solid data showing trends in chronic conditions. It's about true informed consent. If studies showed that vaccinated kids were healthier, that would be great data. (It hasn't ever happened, but it would be great data!) Parents MUST know the true risks as we pile on more shots. Assuming "more is always better" without evidence is reckless. Watch and see why transparency in research is the path to ending this discrimination and restoring trust 👇

The HighWire

14,495 Aufrufe • vor 8 Monaten

The Probiotic Paradox: What Big Pharma & the FDA Don’t Want You to Know Dr. Sabine Hazan, a leading gastroenterologist & clinical trial expert, reveals a critical gap in medicine: The probiotic industry knows bifidobacterium loss is linked to cancer & aging. Yet, they can’t say probiotics may improve longevity or severe disease. Why? The FDA demands clinical trials—even when the science is clear. Doctors are caught in a regulatory trap. Even well-meaning physicians risk FDA backlash for discussing real-world results. But here’s the problem: "If we only approve drugs with a 20% success rate, what happens to the other 80%?" —Dr. Hazan Her work proves innovation can’t stop at FDA approval. When her team used ivermectin/doxycycline/zinc for COVID, ZERO patients died—despite placebo groups crashing. Yet, without billion-dollar trials, such breakthroughs stay in the shadows. The truth? Medicine must evolve beyond red tape. Social media is now a lifeline for sharing unfiltered data & empowering doctors to think beyond the 20%. Follow Dr. Sabine Hazan as she challenges the system—one clinical trial at a time.
3:25

The Probiotic Paradox: What Big Pharma & the FDA Don’t Want You to Know Dr. Sabine Hazan, a leading gastroenterologist & clinical trial expert, reveals a critical gap in medicine: The probiotic industry knows bifidobacterium loss is linked to cancer & aging. Yet, they can’t say probiotics may improve longevity or severe disease. Why? The FDA demands clinical trials—even when the science is clear. Doctors are caught in a regulatory trap. Even well-meaning physicians risk FDA backlash for discussing real-world results. But here’s the problem: "If we only approve drugs with a 20% success rate, what happens to the other 80%?" —Dr. Hazan Her work proves innovation can’t stop at FDA approval. When her team used ivermectin/doxycycline/zinc for COVID, ZERO patients died—despite placebo groups crashing. Yet, without billion-dollar trials, such breakthroughs stay in the shadows. The truth? Medicine must evolve beyond red tape. Social media is now a lifeline for sharing unfiltered data & empowering doctors to think beyond the 20%. Follow Dr. Sabine Hazan as she challenges the system—one clinical trial at a time.

Camus

40,574 Aufrufe • vor 1 Jahr

SOMEONE UPLOADED A REAL FLY BRAIN TO GITHUB. IT IS TRADING CRYPTO RIGHT NOW. This is not an AI. An actual mapped biological connectome (166,700 neurons) is doing real work across 5 insane open-source repositories. 1. stonkfly (646 stars) A fly brain trading Bitcoin. It watches BTC charts through digitized eye cells and places orders via Coinbase API. Profits trigger virtual dopamine neurons. 2. desktop-fly (946 stars) A 3D fly living on your desktop. 668 neurons dodge your mouse cursor using real biological escape circuits. 3. doomfly (263 stars) Plugging raw DOOM pixels directly into optical cells. It failed the learning benchmarks, but the open-source repo is live with all data. 4. fly64 (38 stars) The fly brain plays Super Mario 64. Firing escape neurons forces Mario to jump. Zero machine learning, just mapped biology. 5. ommatid (brand new) A 165,000 neuron connectome running on a basic Raspberry Pi, navigating a physical six-legged robot using a live camera feed. The entire Drosophila connectome is completely free under CC-BY licensing. Full list of repos in first reply ↓
1:19

SOMEONE UPLOADED A REAL FLY BRAIN TO GITHUB. IT IS TRADING CRYPTO RIGHT NOW. This is not an AI. An actual mapped biological connectome (166,700 neurons) is doing real work across 5 insane open-source repositories. 1. stonkfly (646 stars) A fly brain trading Bitcoin. It watches BTC charts through digitized eye cells and places orders via Coinbase API. Profits trigger virtual dopamine neurons. 2. desktop-fly (946 stars) A 3D fly living on your desktop. 668 neurons dodge your mouse cursor using real biological escape circuits. 3. doomfly (263 stars) Plugging raw DOOM pixels directly into optical cells. It failed the learning benchmarks, but the open-source repo is live with all data. 4. fly64 (38 stars) The fly brain plays Super Mario 64. Firing escape neurons forces Mario to jump. Zero machine learning, just mapped biology. 5. ommatid (brand new) A 165,000 neuron connectome running on a basic Raspberry Pi, navigating a physical six-legged robot using a live camera feed. The entire Drosophila connectome is completely free under CC-BY licensing. Full list of repos in first reply ↓

shmidt

33,092 Aufrufe • vor 10 Tagen

Jordi: New Jersey had some success banning a new data center project. What are you tracking right now? Saagar Enjeti: "A lot of these people are actually showing up to town hall meetings. The lines are so long, until 4 a.m. People are bringing their children with signs that say, 'No data centers.'" "You know what it takes for ordinary citizens to show up and stay in line until 4 a.m. to speak against something? It's not a lot of subjects that will inspire that level of hatred." "So for all the data center builders out there, you've got to convince us more that this is actually going to do something for us. Because we're not buying it right now."
1:50

Jordi: New Jersey had some success banning a new data center project. What are you tracking right now? Saagar Enjeti: "A lot of these people are actually showing up to town hall meetings. The lines are so long, until 4 a.m. People are bringing their children with signs that say, 'No data centers.'" "You know what it takes for ordinary citizens to show up and stay in line until 4 a.m. to speak against something? It's not a lot of subjects that will inspire that level of hatred." "So for all the data center builders out there, you've got to convince us more that this is actually going to do something for us. Because we're not buying it right now."

TBPN

73,241 Aufrufe • vor 7 Monaten